Hib CRM197 vaccine conjugate - Nuron

Drug Profile

Hib CRM197 vaccine conjugate - Nuron

Alternative Names: HibTITER; MT-2301; NU300

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator Wyeth
  • Developer Mitsubishi Tanabe Pharma Corporation; Nuron Biotech; Wyeth
  • Class Haemophilus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Haemophilus infections

Most Recent Events

  • 02 Aug 2016 Phase-II development in Haemophilus infections (In infants, Prevention) is ongoing in Japan (Mitsubishi Tanabe Pharma Pipeline, August 2016)
  • 30 Apr 2014 Phase-II clinical trials in Haemophilus infections (Prevention, in infants) in Japan (IM)
  • 31 Mar 2013 Phase-II clinical trials in Haemophilus infections (Prevention, in infants) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top